Zobrazeno 1 - 10
of 1 054
pro vyhledávání: '"LAG3"'
Autor:
Yongfeng Wang, Yanzong Zhao, Guangming Zhang, Yifeng Lin, Chunling Fan, Hui Wei, Shude Chen, Ling Guan, Kan Liu, Shenhan Yu, Liangyin Fu, Jing Zhang, Yuan Yuan, Jin He, Hui Cai
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-17 (2024)
Abstract Lymphocyte activating gene-3 (LAG3) is a distinctive T cell co-receptor that is expressed on the surface of lymphocytes. It plays a special inhibitory immune checkpoint role due to its unique domain and signaling pattern. Our aim is to explo
Externí odkaz:
https://doaj.org/article/43912141bdbf44bda946214736fc3bb9
Autor:
Dianbao Zuo, Yuankui Zhu, Ke Wang, Youjia Qin, Yiyi Su, Sina Lan, Yunyi Li, Shuang Dong, Yinming Liang, Mingqian Feng
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 175, Iss , Pp 116782- (2024)
LAG3 is an inhibitory immune checkpoint expressed on activated T and NK cells. Blocking the interaction of LAG3 with its ligands MHC-II and FGL1 renders T cells improved cytotoxicity to cancer cells. Current study generated a panel of LAG3 monoclonal
Externí odkaz:
https://doaj.org/article/78f6243d35f844769bd6e5093a8a01b6
Publikováno v:
European Journal of Medical Research, Vol 29, Iss 1, Pp 1-17 (2024)
Abstract Background Kidney cancer is an immunogenic solid tumor, characterized by high tumor burden and infiltration of CD8+ T cells. Although immunotherapy targeting the PD1/CTLA-4 axis has demonstrated excellent clinical efficacy, clinical outcomes
Externí odkaz:
https://doaj.org/article/1b9d0df6d753494fa82ca7e2e69f4ee0
Autor:
Rongyang Li, Jianhao Qiu, Zhan Zhang, Chenghao Qu, Zhanpeng Tang, Wenhao Yu, Yu Tian, Hui Tian
Publikováno v:
Cancer Cell International, Vol 23, Iss 1, Pp 1-24 (2023)
Abstract Background Lymphocyte-activation gene 3 (LAG3) is a recently discovered immune checkpoint molecule that has been linked to immunosuppression and the advancement of cancer in different types of solid tumors. This study aimed to evaluate the p
Externí odkaz:
https://doaj.org/article/d4f4f6c19f9144429daa0e23401c3cb7
Autor:
Ken Arimura, Kenzo Hiroshima, Yoji Nagashima, Tadao Nakazawa, Akira Ogihara, Mami Orimo, Yasuto Sato, Hideki Katsura, Masato Kanzaki, Mitsuko Kondo, Etsuko Tagaya
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Lymphocyte-activation gene 3 (LAG3) is an immune checkpoint receptor; novel LAG3 immune checkpoint inhibitors (ICIs) exhibit therapeutic activity in melanoma. The role of LAG3and ICIs of LAG3 are unknown in malignant pleural mesot
Externí odkaz:
https://doaj.org/article/5d57d22dfd674f30914acca0d7681d36
Publikováno v:
Current Oncology, Vol 30, Iss 11, Pp 9789-9812 (2023)
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related deaths in the world. More than half of patients with HCC present with advanced stage, and highly active systemic therapies are crucial for improving outcomes. Immune che
Externí odkaz:
https://doaj.org/article/6833e78effff489e8162d194b22f9d46
Autor:
Qiuyi Li, Chonghao Zhang, Guichuan Xu, Xuekai Shang, Xinmei Nan, Yalan Li, Jiajing Liu, Yanfei Hong, Qing Wang, Guiying Peng
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 171, Iss , Pp 116172- (2024)
Chronic inflammation can promote cancer development as observed in inflammation‐induced colorectal cancer (CRC). However, the poor treatment outcomes emphasize the need for effective treatment. Astragalus polysaccharide (APS), a vital component of
Externí odkaz:
https://doaj.org/article/265f87e7dc964f1f97eb41edd94d7a87
Publikováno v:
Cancer Medicine, Vol 12, Iss 15, Pp 16359-16369 (2023)
Abstract Background Although some patients with diffuse large B‐cell lymphoma (DLBCL) show a response to immunotherapy, there are still many who do not respond. This suggests that various immune checkpoints are complicatedly intertwined in the comp
Externí odkaz:
https://doaj.org/article/4ce3c97660b24e068912b1aa4cba0da8
Publikováno v:
Zhongliu Fangzhi Yanjiu, Vol 50, Iss 7, Pp 710-716 (2023)
Triple-negative breast cancer (TNBC) accounts for approximately 15%–20% of all breast cancers. Patients with TNBC have a rapidly progressive clinical course, an earlier age of onset, faster distant recurrence, and more common visceral metastases as
Externí odkaz:
https://doaj.org/article/d91bef16cd334020bec9ae505fec3f33
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-18 (2023)
Abstract Background Tumour-infiltrating lymphocytes (TILs), including T and B cells, have been demonstrated to be associated with tumour progression. However, the different subpopulations of TILs and their roles in breast cancer remain poorly underst
Externí odkaz:
https://doaj.org/article/285c7edfa62c41228d226bef30b3f707